Skip to main content

Table 1 Hepatocellular carcinoma patient’s characteristic

From: The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia

Variable

No. of Patients (%)

Age

  < 40 years old (n = 12)

9.1%

 40–< 50 years old (n = 71)

53.8%

  ≥ 50 years old (n = 49)

37.1%

Sex

 Male (n = 94)

71.2%

 Female (n = 38)

28.8%

Etiology of HCC

 Hepatitis B (n = 84)

63.6%

 Hepatitis C (n = 22)

16.7%

 Non-Hepatitis B and Non-C (n = 18)

13.6%

 Hepatitis B and Hepatitis C (n = 8)

6.1%

Cirrhosis

 No (n = 59)

44.7%

 Yes (n = 73)

55.3%

BCLC staging

 A (n = 14)

10.6%

 B (n = 56)

42.4%

 C (n = 52)

39.4%

 D (n = 10)

7.6%

Child–Pugh

 A (n = 81)

61.4%

 B (n = 38)

28.8%

 C (n = 13)

9.8%

Number of nodules

 Singular (n = 69)

52.3%

 Multiple (n = 62)

47%

 Diffuse (n = 1)

0.7%

Largest nodule size

  < 20 mm (n = 7)

5.3%

 20–< 50 mm (n = 15)

11.4%

 50–< 100 mm (n = 39)

29.5%

  ≥ 100 mm (n = 71)

53.8%

Metastasis

 No (n = 115)

87.1%

 Yes (n = 17)

12.9%

Portal vein thrombosis

 No (n = 90)

68.2%

 Yes (n = 42)

31.8%